Kytopen has seen an influx of cash of the past few months. Most recently, the biotech raised a large chunk of money in its Series A funding round, which was announced on Tuesday.
Less than a month after appointing a new chief executive officer, Ziopharm Oncology announced a restructure that has resulted in over 50% of its workforce being axed.
On Wednesday, the company said that its adjuvanted protein-based COVID-19 vaccine candidate, dubbed SCB-2019 (CpG 1018/Alum), hit the primary and secondary efficacy endpoints in a Phase II/III clinical trial.
Zai Lab Limited calls itself a growing global biopharmaceutical company and is continuing to live up to that claim with its latest expansion announcement.
Life sciences companies reeled in millions of dollars in Series C financing rounds this week. Here is a look at a few of those companies and what their fresh funds will be used for.
The top three clusters from last year’s list - Greater Boston, San Francisco Bay Area and San Diego - all stood their ground and maintained their rankings from the previous year.
Attralus Therapeutics has had a fresh set of faces shuffling into its executive suite in the past few months. And apparently with new leadership comes new funding opportunities.
